KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other Non-Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Other Non-Current Assets for 6 consecutive years, with $2.4 million as the latest value for Q1 2023.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $2.4 million in Q1 2023 year-over-year; TTM through Mar 2023 was $2.4 million, a N/A change, with the full-year FY2022 number at $3.4 million, down 55.89% from a year prior.
  • Other Non-Current Assets was $2.4 million for Q1 2023 at Twist Bioscience, down from $3.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.7 million in Q3 2021 to a low of $579000.0 in Q4 2019.
  • A 5-year average of $2.5 million and a median of $2.2 million in 2019 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 556.13% in 2019, then plummeted 72.3% in 2020.
  • Twist Bioscience's Other Non-Current Assets stood at $579000.0 in 2019, then surged by 372.37% to $2.7 million in 2020, then tumbled by 42.52% to $1.6 million in 2021, then skyrocketed by 115.33% to $3.4 million in 2022, then plummeted by 30.13% to $2.4 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Other Non-Current Assets are $2.4 million (Q1 2023), $3.4 million (Q3 2022), and $1.6 million (Q4 2021).